GlaxoSmithKline Pakistan Limited was created January 1st, 2001 through the merger of SmithKline and French of Pakistan Limited, Beecham Pakistan (Private) Limited and Glaxo Wellcome (Pakistan) Limited and stands today as the largest pharmaceutical company in Pakistan.
GSK is a long established investor in Pakistan. Our legacy company Glaxo Laboratories Pakistan Ltd. was the first pharmaceutical company to be listed on the Karachi Stock Exchange in 1951.
GSK Pakistan operates mainly in two industry segments: Pharmaceuticals (prescription drugs and vaccines) and consumer healthcare (over-the-counter-medicines, oral care and nutritional care). In Pakistan, the Company deals in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Oncology, Urology, Central Nervous System, Allergy, Cardiovascular and Vitamins therapy areas.
We are committed to our mission of providing patients quality products to help improve the quality of their lives. Some of our leading pharmaceutical brands include Augmentin, Seretide, Amoxil, Velosef, Zantac and Calpol and renowned consumer healthcare brands, which include Panadol, Horlicks, Sensodyne and ENO. Prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix and Priorix Tetra.
Today GSK Pakistan is highly successful business and a market leader by value and volume share in the country. Major competitors are MNCs such as Abbott, Novartis, Pfizer, Sanofi and local companies like Getz and Sami. GSK Pakistan has built a competent commercial capability with a track record of successfully integrating the BMS, UCB, and Stiefel businesses, and building a diverse and profitable business of over 150 brands.
GSK Pakistan presently employs about 2,300 persons across its Sales, Global Manufacturing Services (GMS), Pharma division and Consumer Health Care functions. Our Global Manufacturing Services (GMS) in Pakistan consists of three facilities; West Wharf, F-268 site and Korangi.